Google Inc. (NASDAQ: GOOG) will hold its quarterly conference call to
discuss third quarter 2014 financial results on Thursday, October 16th
at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
The live webcast of Google’s earnings conference call can be accessed at investor.google.com/webcast.html .
MARKHAM, ON--(Marketwired - October 01, 2014) - Extendicare Inc. ("Extendicare" or the "Company") (TSX: EXE) today announced it will hold a conference call and live audio webcast on Friday, November 7, 2014, at 11:00 a.m. (ET) to discuss financial results for the third quarter ended September 30, 2014.
Wayfair, one of the world’s largest online destinations for home
furnishings and décor, today announced the pricing of its initial public
offering of 11,000,000 shares of its Class A common stock at a price to
the public of $29.00 per share.
AAC Holdings, Inc. (NYSE: AAC) (the “Company”), the parent holding
company of American Addiction Centers, Inc., announced today the pricing
of its initial public offering of 5,000,000 shares of common stock at a
price to the public of $15.00 per share, for a total of approximately
$65.6 million of net proceeds after deducting underwriting discounts and
commissions and estimated offering expenses payable by the Company.
Data From Phase 3 RUTHERFORD-2 Study Show Evolocumab Significantly Reduced Mean LDL-C by 59-66 Percent Compared to Placebo in Patients With Heterozygous Familial Hypercholesterolemia
Phase 3 TESLA Data Show Evolocumab Significantly Reduced LDL-C by 31 Percent Compared to Placebo in Patients With Homozygous Familial Hypercholesterolemia THOUSAND OAKS, Calif.
Sign-up for The Lancet Publishes Two Phase 3 Studies Showing Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With Serious Genetic Disorders That Cause High Cholesterol investment picks
TORONTO, ON--(Marketwired - October 01, 2014) - ViXS Systems Inc. (TSX: VXS), a pioneer and leader in media processing solutions, is pleased to announce that Sally Daub, President and CEO of ViXS, has been appointed to Consumer Electronics Association's (CEA)® Board of Industry Leaders (BIL). The BIL is comprised of 45 consumer technology industry leaders and serves CEA and its Executive Board in an advisory role, helping to set priorities for association activities and industry public policy positions.
Deutsche Bank today announced its appointment as successor depositary
bank for the sponsored Level II NYSE-listed American Depositary Receipt
(ADR) program of James Hardie Industries plc (James Hardie).
James Hardie (NYSE:JHX) is a world-leading manufacturer of fiber-cement
Minnesota Power, a division of ALLETE, Inc. (NYSE: ALE) said today Essar
Steel’s announcement that the company has successfully completed the
necessary financing to complete construction of its open-pit iron ore
mine crushing, concentrating and pelletizing facilities is good news for
Law office of Brodsky & Smith, LLC announces that it is investigating
potential claims against the Board of Directors of LipoScience, Inc.
(“LipoScience" or the “Company”) (Nasdaq: LPDX) relating to the proposed
acquisition by Laboratory Corporation of America Holdings.
The securities litigation law firm of Brower Piven, A Professional
Corporation, has commenced an investigation into possible breaches of
fiduciary duty and other violations of state law by the Board of
Directors of Move, Inc. (“Move” or the “Company”) (Nasdaq: MOVE)
relating to the proposed buyout of the Company by News Corp.
Kirby McInerney LLP announced today that a class action lawsuit has been
filed in the United States District Court for the Southern District of
New York on behalf of investors who acquired Altair Nanotechnologies,
Inc. (“Altair” or the “Company”) (OTC: ALTI) securities during the
period from May 15, 2013 through September 4, 2014 (the “class period”).
Pursuant to applicable law, investors have until November 25, 2014 to
file a motion to be appointed as lead plaintiff in the investor lawsuit.
By Jeremy Wiesen
There is a solution to some of the U.S.'s biggest economic challenges: unemployment; questionably adequate GDP growth; insufficient funds to repair aging infrastructure, and dependence on fossil fuels.
By Wallace Witkowski, MarketWatch
SAN FRANCISCO (MarketWatch) -- Shares of Esperion Therapeutics Inc. rallied after the drug developer said its treatment significantly lowered bad cholesterol in patients enrolled in a clinical trial.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.